Similarly to previous findings, a retrospective analysis based on a pooled cohort of 936 NPM1-mutated AML patients treated as part of the multicenter trials of the Study Alliance Leukemia (SAL) revealed that MDS-related gene mutations do not have an adverse effect on the treatment outcome of NPM1mut patients [23]. Here, NPM1 is linked to myelodysplastic syndrome.